Phung explained that prior response often guides selection: Patients who respond poorly to frontline therapy may move to CAR ...

Across conversations on precision oncology, malignant hematology, cellular therapies, and social determinants of health (SDOH ...

Value-based oncology care requires balancing rapid innovation with operational sustainability, equitable access, and ...

Marc S. Raab, MD, PhD, discusses the different ways that combination therapy that includes teclistamab can benefit patients ...

Metabolic reprogramming in fibrotic lung diseases involves key metabolites like lactate, succinate, and 2-hydroxyglutarate, ...

1. Garg S, Donnenfeld E, Sheppard J, Epitropoulos A, Brady TC. Reproxalap improves ocular redness, tear production, and ...

Panelists discuss how real-world outcomes inform patient conversations and support shared decision-making for third-line ...

Panelists explain that in the absence of head-to-head trial data, real-world evidence (RWE) becomes crucial in guiding ...

Mutations in ZRSR2 have been linked with disease progression in patients with JAK2 V617R – driven myeloproliferative ...

Real-world evidence helps pharmaceutical companies and payers communicate more effectively. In this Q&A, Cate Lockhart, PharmD, PhD, chief science officer of the Academy of Managed Care Pharmacy (AMCP ...

Equitable access to genomic testing for NSCLC patients is vital for advanced therapy access, with strategies including commercial contracts and financial assistance programs. Financial toxicity and ...

Neoadjuvant immunochemotherapy shows higher pCR and MPR rates compared to chemotherapy alone in LS-SCLC patients, suggesting enhanced tumor regression before surgery. Propensity score matching ...